Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis

AIMS: To evaluate the efficacy and safety of vernakalant for the cardioversion of atrial fibrillation (AF). METHODS AND RESULTS: We reviewed the literature for randomized trials that compared vernakalant to another drug or placebo in patients with AF of onset ≤7 days. We used a random-effects model...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Europace
Asıl Yazarlar: McIntyre, William F, Healey, Jeff S, Bhatnagar, Akash K, Wang, Patrick, Gordon, Jacob A, Baranchuk, Adrian, Deif, Bishoy, Whitlock, Richard P, Belley-Côté, Émilie P
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Clinical Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6680366/
https://ncbi.nlm.nih.gov/pubmed/31292622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euz175
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller